Is it the Right Time to Hold STERIS Stock in Your Portfolio?
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments.
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Steris (STE) International Revenue in Focus: Trends and Expectations
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
STERIS plc (STE) Q3 2025 Earnings Call Transcript
STERIS plc (NYSE:STE ) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and Chief Financial Officer Dan Carestio – President and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Brett Fishbin – KeyBanc Michael Polark – Wolfe Research Jason Bednar – Piper Sandler Patrick Wood – Morgan Stanley Mike Matson – Needham & Company Dave Turkaly – Citizens Operator Good day, and welcome to the STERIS plc Third Quarter 2025 Conference Call. All participants will be in a listen-only mode.
STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.
Steris (STE) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Matches Q3 Earnings Estimates
Steris (STE) came out with quarterly earnings of $2.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $2.22 per share a year ago.
Steris lowers annual profit forecast due to a stronger dollar
Medical equipment maker Steris lowered its annual profit forecast on Wednesday, citing the impact of a stronger dollar.
Can Steris (STE) Keep the Earnings Surprise Streak Alive?
Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street's Insights Into Key Metrics Ahead of Steris (STE) Q3 Earnings
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
STE Gears Up for Q3 Earnings: Here's What You Need to Know
STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.
